Genetic determinants: Is there an "atherosclerosis gene"?

Acta Medica Austriaca

Volumn 31, Issue 1, 2004, Pages 1-7

  Prager, Gerald W ^a   Binder, Bernd R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Cholesterol; Inflammation; Plaque stability

Indexed keywords

APOLIPOPROTEIN B100; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR2; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PADGEM PROTEIN; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; BLOOD FLOW; CELL ACTIVATION; CELL ADHESION; CELL LINEAGE; CELL MIGRATION; CELL NUCLEUS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR SPACE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC VARIABILITY; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; LAMINAR FLOW; LEUKOCYTE; LIPID OXIDATION; LIPID PEROXIDATION; LIPID STORAGE; MACROPHAGE; MONOCYTE; NONHUMAN; RESTENOSIS; REVIEW; SHEAR STRESS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TURBULENT FLOW; VASCULAR DISEASE; VIRUS; VIRUS INFECTION;

ARTERIOSCLEROSIS; BLOOD FLOW VELOCITY; HUMANS; INFLAMMATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; STRESS, MECHANICAL;

EID: 1642378586     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) Study Group (1998) N Engl J Med 339: 1349-1357
2. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P (2002) All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 90: 764-769
3. Baeuerle PA (1998) IkappaB-NF-KappaB Structures: at the interface of inflammation. Control Cell 95: 729-731
4. Baeuerle PA, Baltimore DI (1988) Kappa B: a specific inhibitor of the NF-Kappa B transcription factor. Science 242: 540-546
5. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA (1998) Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338: 1650-1656
6. Berliner J (2002) Introduction: lipid oxidation products and atherosclerosis. Vascul Pharmacol 38: 187-191
7. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized LDL. Nat Med 9: 736-743
8. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N (2002) Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419: 77-81
9. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N (2002) Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 99: 199-206
10. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA (1998) A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101: 353-363
11. Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897
12. Carmeliet P (2000) Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 105: 1519-1520
13. Cercek B, Yamashita M, Dimayuga P, Zhu J, Fishbein MC, Kaul S, Shah PK, Nilsson J, Regnstrom J (1997) Nuclear Factor-KappaB activity and arterial response to balloon injury. Atherosclerosis 131: 59-66
14. Cybulsky MI, Gimbrone MA Jr (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251: 788-791
15. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD (1999) Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103: 1597-1604
16. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, Smith JD (1999) Genetic background determines the extent of atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 19: 1960-1968
17. Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG (2003) Shear stress regulates endothelial nitric oxide synthase promoter activity through nuclear factor kappa-B binding. J Biol Chem
18. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence. Circulation
19. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA (2000) The transcription factor NF-Kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20: E83-E88
20. de Nigris F, Lerman LO, Ignarro SW, Sica G, Lerman A, Palinski W, Ignarro LJ, Napoli C (2003) Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proc Natl Acad Sci (USA) 100: 1420-1425
21. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD (1998) The combined role of P-and E-selectins in atherosclerosis. J Clin Invest 102: 145-152
22. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL (2000) Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105: 1049-1056
23. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-2503
24. Gimbrone MA Jr, Resnick N, Nagel T, Khachigian LM, Collins T, Topper JN (1997) Hemodynamics, endothelial gene expression, and atherogenesis. Ann NY Acad Sci 811: 1-10
25. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G (2000) Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 902: 230-239
26. Goldstein JL, Brown MS (1977) The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897-930
27. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773-778
28. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I, De Martin R, Binder BR (2003) Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression. Blood 101: 3042-3048
29. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281
30. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C (1997) IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 99: 2752-2761
31. Hansson GK, Jonasson L, Seifert PS, Stemme S (1989) Immune mechanisms in atherosclerosis. Arteriosclerosis 9: 567-578
32. Heinecke JW (1998) Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141: 1-15
33. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600
34. Hobbs HH, Russell DW, Brown MS, Goldstein JL (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24: 133-170
35. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, De Martin R (2000) Activation of NF-Kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 275: 22064-22068
36. Horkko S, Binder CJ, Shaw PX, Chang MK, Silverman G, Palinski W, Witztum JL (2000) Immunological responses to oxidized LDL. Free Radic Biol Med 28: 1771-1779
37. Ishii H, Tezuka T, Ishikawa H, Takada K, Oida K, Horie S (2003) Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. Blood 101: 4765-4774
38. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
39. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N (2000) Enhanced atherosclerosis and kidney dysfunction in ENOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105: 451-458
40. Kronke G, Bochkov VN, Huber J, Gruber F, Bluml S, Furnkranz A, Kadl A, Binder BR, Leitinger N (2003) Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of CAMP-responsive element binding protein (CREB). J Biol Chem
41. Landry DB, Couper LL, Bryant SR, Lindner V (1997) Activation of the NF-Kappa B and I Kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 151: 1085-1095
42. Lee RT, Libby P (1997) The unstable atheroma. Arterioscler Thromb Vasc Biol 17: 1859-1867
43. Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8: 240-246
44. Leitinger N, Tyner TR, Oslund L, Rizza C, Subbanagounder G, Lee H, Shih PT, Mackman N, Tigyi G, Territo MC, Berliner JA, Vora DK (1999) Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci (USA) 96: 12010-1205
45. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874
46. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143
47. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241
48. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P (2002) Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22: 499-505
49. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P (1997) Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96: 396-399
50. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, Hofer E (2001) Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 15: 230-242
51. Muller K, Carpenter KL, Mitchinson MJ (1998) Cell-mediated oxidation of LDL: comparison of different cell types of the atherosclerotic lesion. Free Radic Res 29: 207-220
52. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM (1996) The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler Thromb Vasc Biol 16: 831-842
53. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orisio S, Remuzzi G, Remuzzi A (1995) Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 76: 536-543
54. Otterbein LE, Bach FH, Alam J, Soares M, Tao LuH, Wysk M, Davis RJ, Flavell RA, Choi AM (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6: 422-428
55. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, Soares MP (2003) Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med 9: 183-190
56. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA (1993) Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 92: 471-478
57. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82
58. Ross R (1999) Atherosclerosis is an inflammatory disease. Am Heart J 138(5 Pt 2): 419-420
59. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126
60. Schwab US, Ausman LM, Vogel S, Li Z, Lammi-Keefe CJ, Goldin BR, Ordovas J M, Schaefer EJ, Lichtenstein AH (2000) Dietary cholesterol increases the susceptibility of low density lipoprotein to oxidative modification. Atherosclerosis 149: 83-90
61. Schwenke DC, Carew TE (1989) Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis 9: 895-907
62. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105: 1731-1740
63. Shiffman D, Porter JG (2000) Gene expression profiling of cardiovascular disease models. Curr Opin Biotechnol 11: 598-601
64. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514
65. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793
66. Stehlik C, De Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J (1998) Nuclear factor (NF)-KappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188: 211-216
67. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924
68. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci (USA) 92: 3893-3897
69. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T (1997) A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296
70. Thurberg BL, Collins T (1998) The nuclear factor-Kappa B/inhibitor of Kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9: 387-396
71. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252
72. Wick G, Romen M, Amberger A, Metzler B, Mayr M, Falkensammer G, Xu Q (1997) atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J 11: 1199-1207
73. Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, De Martin R (1996) Inhibition of endothelial cell activation by adenovirus-mediated expression of I Kappa B alpha, an inhibitor of the transcription factor NF-Kappa B. J Exp Med 183: 1013-1022
74. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342: 154-160